Orexo AB, the Swedish specialty pharmaceutical company, has appointed Henrik Juuel to the position of chief financial officer, succeeding Carl-Johan Blomberg. Mr Juuel has previously been CFO at Denmark-based NNE Pharmaplan, a consultancy, and at GN Resound, a producer of hearing devices. The management change comes as Orexo prepares to commercialise Zubsolv, a product to treat opioid dependence that recently received approval from the US Food and Drug Administration.
Orexo announced the appointment on 15 July 2013.
Copyright 2013 Evernow Publishing Ltd